Provenge sales a mixed bag for Dendreon in third quarter
This article was originally published in Scrip
Executive Summary
Dendreon showed year-over-year improvements for Provenge (sipuleucel-T) with third quarter 2012 sales totaling $78 million, representing a 27% increase from the same period in 2011, but July-to-September sales for the autologous cellular immunotherapy for prostate cancer patients slipped another 2.5% from the second quarter after declining 2.4% between the first and second quarters of this year (scripintelligence.com, 31 July 2012).